GSK plc position in CRSP
Crispr Therapeutics Ag · Health Care
GSK plc reported holding 2,608,419 shares of CRSP (Crispr Therapeutics Ag) in its Q3 2026 13F filing — a position valued at US$144.3M, representing 29.03% of its reported portfolio and ranking #1 among its reported holdings. GSK plc has disclosed CRSP holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-06 · Source: SEC EDGAR Form 13F-HR
How GSK plc's CRSP position evolved
GSK plc first disclosed a stake in CRSP in Q4 2025 at 3,220,627 shares (US$168.9M). The position peaked in Q2 2026 at 3,220,627 shares, worth US$175.7M. Across 4 filings, GSK plc increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 2,608,419 shares valued at US$144.3M — a reduction of -612,208 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 3.22M | $168.89M | New |
| Q1 2026 | 3.22M | $153.21M | Hold |
| Q2 2026 | 3.22M | $175.65M | Hold |
| Q3 2026 | 2.61M | $144.30M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRSP and 13F data
CRSP (Crispr Therapeutics Ag) is a Health Care company. 31 other funds we track also report a position in CRSP — the largest reported positions include ARK Invest (US$516.0M), Orbis Allan Gray Ltd (US$297.2M), SR ONE CAPITAL MANAGEMENT, LP (US$111.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRSP
- ARK Invest 9.46M sh · $516.00M · Q2 2026
- Orbis Allan Gray Ltd 5.45M sh · $297.20M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 2.04M sh · $111.19M · Q2 2026
- Amova Asset Management Americas, Inc. 1.72M sh · $93.76M · Q2 2026
- EcoR1 Capital, LLC 1.39M sh · $75.77M · Q2 2026
- NEA Management Company, LLC 1.06M sh · $57.73M · Q2 2026
FAQ
How long has GSK plc held CRSP?
GSK plc has disclosed CRSP holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is GSK plc's current position in CRSP?
As of Q3 2026, GSK plc holds 2.61M shares of CRSP (Crispr Therapeutics Ag), valued at $144.30M, representing 29.03% of its reported portfolio and ranking #1.
Has GSK plc been buying or selling CRSP?
In the latest 13F filing (Q3 2026), GSK plc reduced its position in CRSP. The position peaked in Q2 2026 at 3.22M shares.
Which other funds hold CRSP?
Other major institutional holders of CRSP include ARK Invest, Orbis Allan Gray Ltd, SR ONE CAPITAL MANAGEMENT, LP, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.